Atai Life Sciences N.V. has entered into an underwriting agreement for a public offering of 26,190,477 common shares at $2.10 per share, aiming to raise approximately $51.4 million for general corporate purposes and clinical development, with an option for the underwriter to purchase an additional 3,928,571 shares. The company also reported positive clinical results from its investments in Beckley Psytech and Recognify Life Sciences, indicating advancements in their product candidates.